Related Experiment Video
Updated: May 4, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Morphine is associated with acute chest syndrome in children hospitalized with sickle cell disease
Catherine S Birken1, Amina Khambalia, Annie Dupuis
1Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada. catherine.birken@sickkids.ca
Insights
Children with sickle cell disease (SCD) receiving morphine for pain may have an increased risk of acute chest syndrome (ACS). Close monitoring for ACS is recommended during hospitalization for SCD patients on morphine.
Area of Science:
- Pediatric Hematology
- Pain Management
- Sickle Cell Disease Research
Background:
- Sickle cell disease (SCD) is a genetic blood disorder.
- Acute chest syndrome (ACS) is a common and serious complication of SCD.
- Pain management is crucial for hospitalized SCD patients.
Purpose of the Study:
- To investigate the association between intravenous morphine use and the development of acute chest syndrome (ACS).
- To assess the risk of ACS in children with homozygous hemoglobin S SCD receiving morphine for acute pain.
Main Methods:
- Retrospective review of health records for SCD patients aged 2-18 years hospitalized with acute pain.
- Comparison of morphine dosage in patients who developed ACS (cases) versus those who did not (controls).
- Survival analysis to determine the association between morphine dose and ACS incidence.
Main Results:
- Morphine dosage in the hours preceding ACS was significantly associated with its development.
- Patients who developed ACS received a higher mean morphine dose (40 microg/kg) compared to controls (34 microg/kg) one hour before ACS.
- Each additional 10 microg/kg of morphine increased the risk of ACS by 23%.
Conclusions:
- Intravenous morphine administration is associated with an increased risk of ACS in children with SCD.
- Close observation for ACS symptoms is recommended for hospitalized SCD patients receiving morphine.
- Further research may explore optimal pain management strategies to mitigate ACS risk.
Objective:
To determine if intravenous morphine is associated with acute chest syndrome (ACS) in children with homozygous for hemoglobin S sickle cell disease (SCD) hospitalized with acute pain.
Methods:
Health records of patients with homozygous for hemoglobin S SCD aged 2 to 18 years hospitalized with acute pain were reviewed. Patients developed ACS at least 12 hours after emergency department triage; controls did not develop ACS. Survival analyses were performed.
Results:
There were 38 cases and 45 randomly selected controls. The mean hourly dose of morphine 1, 2, and 3 hours before ACS and cumulative mean morphine dose up to 5 hours before ACS were significantly associated with ACS (P < .05). Adjusted analysis showed that 1 hour before ACS, the mean morphine dose was significantly higher in cases (40 microg/kg) compared with controls (34 microg/kg), and the risk of ACS increased by 23% for each additional 10 microg/kg of morphine received (P = .02).
Conclusions:
We recommend close observation for ACS in hospitalized patients with SCD who are receiving morphine.
Related Concept Videos
Opioid Analgesics: Morphine and Other Natural Cogeners
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Toxidromes: Clinical Features
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...

